华兰疫苗(301207) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥499,312,414.08, a decrease of 63.87% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥206,521,700.73, down 62.93% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥188,217,171.83, reflecting a decline of 65.83% compared to the previous year[6]. - The company reported a basic earnings per share of ¥0.5192, down 66.45% year-on-year[6]. - Net profit for the current period was ¥504,708,026.11, a decrease of 4.4% from ¥528,169,121.73 in the previous period[32]. - Basic and diluted earnings per share for the current period were 1.2904, compared to 1.4671 in the previous period[35]. Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥7,173,842,560.89, an increase of 58.59% from the end of the previous year[6]. - The total assets increased to ¥7,173,842,560.89 from ¥4,523,446,917.50, showing strong growth in the company's asset base[28]. - The total liabilities decreased slightly to ¥1,696,840,935.11 from ¥1,715,354,421.76, indicating improved financial stability[28]. - The equity attributable to shareholders increased by 95.04% year-on-year, amounting to ¥5,477,001,625.78[6]. - The equity attributable to shareholders of the parent company rose to ¥5,477,001,625.78 from ¥2,808,092,495.74, reflecting strong retained earnings growth[28]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥35,484,779.81, a significant decrease of 111.81% compared to the previous year[11]. - Cash inflow from operating activities totaled 967,781,400.50, down from 1,411,702,881.33 in the previous period, representing a decrease of approximately 31%[36]. - Net cash flow from operating activities was -35,484,779.81, a significant decline from 300,587,782.41 in the previous period[36]. - Cash inflow from investment activities was 4,331,189,120.42, compared to 2,265,110,874.30 in the previous period, indicating an increase of approximately 91%[39]. - Net cash flow from investment activities was -1,147,864,950.82, worsening from -644,256,999.76 in the previous period[39]. - Cash inflow from financing activities amounted to 2,554,768,800.00, up from 800,000,000.00 in the previous period[39]. - Net cash flow from financing activities was 1,964,579,300.01, compared to 591,522,222.12 in the previous period, showing a substantial increase[39]. - The ending balance of cash and cash equivalents was 896,022,620.53, up from 599,048,768.52 in the previous period[39]. - The company reported a net increase in cash and cash equivalents of 781,229,569.38, compared to 247,853,004.77 in the previous period[39]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,460[15]. - The largest shareholder, Hualan Biological Engineering Co., Ltd., holds 67.50% of shares, totaling 270,000,000 shares[15]. - The total number of preferred shareholders is not applicable, indicating no preferred shares were issued[18]. - The company has a total of 366,071,060 restricted shares at the end of the reporting period[21]. - The company plans to lift restrictions on 270,000,000 shares by August 18, 2025, which were issued before the initial public offering[18]. - The top ten shareholders do not have any known relationships or agreements that would classify them as acting in concert[17]. Expenses and Investments - The company experienced a 32.88% increase in sales expenses, totaling ¥636,720,642.53, due to increased marketing efforts[11]. - Total operating costs amounted to ¥1,007,106,441.39, up from ¥807,739,933.50, reflecting a significant increase in sales expenses[29]. - Research and development expenses were ¥110,099,858.88, slightly up from ¥108,705,277.49, indicating continued investment in innovation[29]. - The company has invested in new product development and market expansion strategies, although specific figures are not disclosed in the provided content[20]. Tax and Future Outlook - The company reported a significant increase in deferred income tax assets, rising to ¥197,459,746.95 from ¥182,899,117.57, suggesting potential future tax benefits[28]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[31]. Audit Status - The third quarter report was not audited[40].